Ion; 2011.doi:10.11861475-2875-12-450 Cite this article as: Quashie et
Ion; 2011.doi:10.11861475-2875-12-450 Cite this article as: Quashie et al.: A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs. Malaria Journal 2013 12:450.Submit your subsequent manuscript to BioMed Central and take complete benefit of:Practical on-line submission Thorough peer critique No space constraints or color figure charges Quick publication on acceptance Inclusion in PubMed, CAS, Scopus and Google GSTP1, Human Scholar Study which is freely offered for redistributionSubmit your manuscript at biomedcentralsubmit
HIPPOKRATIA 2013, 17, 2:187-CASE REPORTBleomycin cardiotoxicity in the course of chemoAmphiregulin Protein Accession therapy for an ovarian germ cell tumorDidagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C1st Department of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, Thessaloniki, GreeceAbstract Introduction: Platinum-based chemotherapeutic regimens, such as BEP (bleomycin, etoposide, cisplatin) represent the normal of care, initially line therapy in non-epithelial ovarian tumours. Cardiovascular toxicity is a uncommon adverse effect of bleomycin. Case Report: A 41-year-old woman with ovarian granulosa tumor, treated with initially line BEP chemotherapy seasoned chest discomfort quickly progressing to serious precordial pain in the course of bleomycin infusion. The infusion was stopped and electrocardiographic adjustments indicative of myocardial ischemia have been revealed. Anti-anginal and anti-thrombotic therapy was introduced. Cardiac enzymes were not elevated and echocardiographic findings showed no wall motion abnormalities. Twenty four hours following the episode the elctrocardiographic modifications insisted and chemotherapy was decided to be continued, excluding bleomycin, with no symptom recurrence. Discussion: Cardiovascular complications pose a uncommon but prospective fatal adverse effect of BEP chemotherapy and really should be meticulously addressed, in particular in patients with extra cardiovascular danger elements. Physicians coping with bleomycin-based therapies may perhaps come across this information useful for a far more comprehensive evaluation of chest pain syndromes in these individuals. Hippokratia 2013, 17, 2: 1787-188 Key phrases: BEP chemotherapy, ovarian cancer, cardiotoxicity, myocardial ischemia, chest painCorresponding Author: Anastasios Boutis, 1st Division of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, 54007, Thessaloniki, Greece, tel.: 302310898711, 306937040299, fax:302310845514, e-mail: alboutisotenet.grIntroduction BEP (bleomycin, etoposide, cisplatin) chemotherapeutic regimen represents the typical of care initial line therapy in non-epithelial ovarian tumours1. Cardiovascular toxicity can be a uncommon adverse effect of bleomycin and can be expressed clinically as hypotension, pericarditis, acute substernal chest pain, coronary artery illness, myocardial ischemia, myocardial infarction, cerebral vascular accident and Raynaud’s phenomenon2. Case report A 41-year-old woman with sophisticated recurrent ovarian cancer (adult granulosa cell tumor, initial stage pT2b pN1 M0, FIGO IIIC, four years prior to) was treated with initial line platinum-based chemotherapy. Pre-treatment cardiovascular danger elements incorporated arterial hypertension (nicely controlled with angiotensin II receptor blockers) and obesity (BMI: 40.three Kgm2). Baseline cardiologic evaluation with ECG and echocardiogram just just before initiation of chemotherapy was unremarkable. For the duration of the initial cycle of therapy and during the bleomycin infusion, ch.